| Multiple Sclerosis
Lemtrada vs Tysabri
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis.Deep comparison between: Lemtrada vs Tysabri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTysabri has a higher rate of injection site reactions vs Lemtrada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tysabri but not Lemtrada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lemtrada
Tysabri
At A Glance
IV infusion
Annual treatment courses
Anti-CD52 monoclonal antibody
IV infusion
Every 4 weeks
alpha4-integrin antagonist
Indications
- Multiple Sclerosis
- Multiple Sclerosis
- Crohn Disease
Dosing
Multiple Sclerosis First course: 12 mg/day IV infusion on 5 consecutive days; second course: 12 mg/day on 3 consecutive days 12 months after first course; subsequent courses: 12 mg/day on 3 consecutive days as needed, at least 12 months after the last prior dose. Premedicate with high-dose corticosteroids for the first 3 days of each course; administer antiviral prophylaxis starting on the first day of each course for a minimum of 2 months or until CD4+ count >= 200 cells/microliter.
Multiple Sclerosis 300 mg IV infusion over one hour every four weeks.
Crohn Disease 300 mg IV infusion over one hour every four weeks; discontinue if no therapeutic benefit by 12 weeks of induction therapy or if concomitant corticosteroids cannot be tapered within six months of starting therapy.
Contraindications
- Known hypersensitivity or anaphylactic reaction to alemtuzumab or any excipient
- HIV infection
- Active infection
- Progressive multifocal leukoencephalopathy (PML), current or historical
- Previous hypersensitivity reaction to TYSABRI, ranging from urticaria to anaphylaxis
Adverse Reactions
Most common (>=10%) Rash, headache, pyrexia, nasopharyngitis, nausea, urinary tract infection, fatigue, insomnia, upper respiratory tract infection, herpes viral infection, urticaria, pruritus, thyroid gland disorders, fungal infection, arthralgia, pain in extremity, back pain, diarrhea, sinusitis, oropharyngeal pain, paresthesia, dizziness, abdominal pain, flushing, vomiting
Serious Autoimmunity, infusion reactions, stroke and cervicocephalic arterial dissection, malignancies, immune thrombocytopenia, glomerular nephropathies including anti-GBM disease, thyroid disorders, other autoimmune cytopenias, autoimmune hepatitis, hemophagocytic lymphohistiocytosis, adult onset Still's disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, acquired hemophilia A, immune-mediated colitis, infections, progressive multifocal leukoencephalopathy, acute acalculous cholecystitis, pneumonitis
Postmarketing Acquired hemophilia A, neutropenia, thrombocytopenia, thrombotic thrombocytopenic purpura, stroke (hemorrhagic and ischemic), cervicocephalic arterial dissection, cholecystitis, immune-mediated colitis, autoimmune hepatitis, viral hepatitis, opportunistic infections, progressive multifocal leukoencephalopathy, vasculitis, Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis, sarcoidosis, adult onset Still's disease, autoimmune encephalitis, myasthenia gravis, Lambert-Eaton myasthenic syndrome, pulmonary alveolar hemorrhage, alopecia
Most common (>=10%) Headache, fatigue (MS and CD); arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea, rash (MS); upper respiratory tract infection, nausea (CD).
Serious Progressive multifocal leukoencephalopathy (PML), herpes infections, hepatotoxicity, hypersensitivity and antibody formation, immunosuppression and infections, hematological abnormalities.
Postmarketing Hemolytic anemia, thrombocytopenia (including immune thrombocytopenic purpura).
Pharmacology
Alemtuzumab is a humanized IgG1 kappa monoclonal antibody that binds to CD52, a cell surface antigen on T and B lymphocytes, natural killer cells, monocytes, and macrophages, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis; the precise mechanism by which this exerts therapeutic effects in MS is unknown.
Alpha4-integrin antagonist; recombinant humanized IgG4 monoclonal antibody that binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins on leukocytes, blocking their adhesion to VCAM-1 and MAdCAM-1 and inhibiting transmigration into inflamed parenchymal tissue in multiple sclerosis and Crohn's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lemtrada
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Tysabri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Lemtrada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tysabri
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lemtrada
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Tysabri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LemtradaView full Lemtrada profile
TysabriView full Tysabri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.